Congestive heart failure natural history: Difference between revisions
Jump to navigation
Jump to search
| (18 intermediate revisions by 11 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | __NOTOC__ | ||
{{CMG}}; | {| class="infobox" style="float:right;" | ||
|- | |||
| [[File:Siren.gif|30px|link= Heart failure resident survival guide]]|| <br> || <br> | |||
| [[Heart failure resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
{{Congestive heart failure}} | |||
{{CMG}}; {{AE}} {{CZ}}; Saleh El Dassouki, M.D. [mailto:seldassouki@hotmail.com]; Atif Mohammad, M.D. | |||
==Overview== | ==Overview== | ||
Heart failure is associated with significantly reduced physical and mental health, resulting in a markedly decreased [[quality of life]]. Congestive heart failure is also associated with a poor prognosis. If left untreated, heart failure may result in death due to complications associated with the condition. Heart failure resulting from atherosclerotic coronary artery disease has been shown to be associated with higher incidence of fatal events compared to heart failure that results from other cardiac diseases. Heart failure is a progressive disease with a major impact on the patient's quality of life. With the exception of heart failure caused by reversible conditions, the condition usually worsens with time. Although some people survive many years, progressive disease is associated with an overall annual mortality rate of 10%. In the Framingham experience, 80% of men and 70% of women with heart failure who were under 65 years of age had died within 8 years of the diagnosis. | |||
== Natural History == | |||
* If left untreated, heart failure may result in death due to complications associated with the condition. Heart failure is a progressive disease with a major impact on the patient's quality of life. | |||
* Heart failure resulting from atherosclerotic coronary artery disease has been shown to be associated with higher incidence of fatal events compared to heart failure that results from other cardiac diseases | |||
* Initiation of therapy for heart failure may lead to stabilization of the patient's clinical condition which is referred to as the stability phase.<ref name="pmid27371510">{{cite journal |vauthors=Chaudhry SP, Stewart GC |title=Advanced Heart Failure: Prevalence, Natural History, and Prognosis |journal=Heart Fail Clin |volume=12 |issue=3 |pages=323–33 |date=July 2016 |pmid=27371510 |doi=10.1016/j.hfc.2016.03.001 |url=}}</ref> | |||
* Months to years following the stability phase, the patient functional status may decline resulting in multiple hospitalizations and eventually the condition may become refractory to treatment whn ventricular remodeling sets in.<ref name="pmid22392529">{{cite journal |vauthors=Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Riegel B, Spertus JA |title=Decision making in advanced heart failure: a scientific statement from the American Heart Association |journal=Circulation |volume=125 |issue=15 |pages=1928–52 |date=April 2012 |pmid=22392529 |pmc=3893703 |doi=10.1161/CIR.0b013e31824f2173 |url=}}</ref> | |||
* Once refractory, heart failure may be managed titration of pharmacological therapy and by the use to left ventricular assist devices and cardiac transplantation. | |||
* Common Triggers for referral to [[heart failure]] specialist are:<ref name="pmid33755495">{{cite journal |vauthors=Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML, Kirklin JK, Weintraub WS |title=2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure) |journal=Circ Cardiovasc Qual Outcomes |volume=14 |issue=4 |pages=e000102 |date=April 2021 |pmid=33755495 |pmc=8059763 |doi=10.1161/HCQ.0000000000000102 |url=}}</ref> | |||
* New-onset [[HF]] (regardless of [[EF]]): Refer for evaluation of [[etiology]], therapies base on the guideline, evaluation by [[advanced imaging]], [[endomyocardial biopsy]], or [[genetic]] testing | |||
* Chronic [[HF]] with high-risk features, such as development or persistence of one or more of the following risk factors: | |||
*: Need for chronic intravenous [[inotropes]] | |||
*: Persistent [[NYHA]] [[functional class]] III–IV [[symptoms]] of [[congestion]] or profound [[fatigue]] | |||
*: [[Systolic blood pressure]] ≤90 mm Hg or symptomatic [[hypotension]] | |||
*: [[Creatinine]] ≥1.8 mg/dL or BUN ≥43 mg/dL | |||
*:Initiation of [[atrial fibrillation]], [[ventricular arrhythmias]], or repetitive [[ICD shocks]] | |||
*: Two or more emergency department visits or [[hospitalizations]] for worsening [[HF]] in the prior 12 months | |||
*: Inability to tolerate optimally dosed [[beta-blockers]] and/or [[ACEI]]/[[ARB]]/[[ARNI]] and/or [[aldosterone antagonists]] | |||
*: [[Clinical deterioration]], by worsening [[edema]], increase [[biomarkers]] ([[BNP]], [[NT-proBNP]], others), worsened [[exercise]] testing, decompensated [[hemodynamics]], or evidence of progressive [[remodeling]] on [[imaging]] | |||
*: High [[mortality]] risk using a validated risk model such as the [[Seattle Heart Failure Model]] | |||
* Persistently reduced [[LVEF]] ≤ 35% despite [[GDMT]] for ≥3 months: refer for [[device therapy]] in those [[patients]] without prior placement of [[ICD ]] or [[CRT]], unless [[device therapy]] is contraindicated or inconsistent with overall goals of care | |||
*Second [[opinion]] needed regarding [[etiology]] of [[HF]], for example: | |||
*:[[ Coronary ischemia]] and possibility of the need for [[revascularization]] | |||
*: [[Valvular heart disease]] and possibility of the need for [[valve repair]] | |||
*: Suspected [[myocarditis]] | |||
*: Suspected specific [[cardiomyopathies]] ( [[hypertrophic cardiomyopathy]], [[arrhythmogenic right ventricular dysplasia]], [[Chagas disease]], [[restrictive cardiomyopathy]], [[cardiac sarcoidosis]], [[amyloid]], [[aortic stenosis]]) | |||
* Annual review needed for [[patients]] with established advanced [[HF]] | |||
* Assessment of [[patient]] for participation in a [[clinical trial]] | |||
==Complications== | ==Complications== | ||
| Line 26: | Line 63: | ||
==Prognosis== | ==Prognosis== | ||
===Risk Stratification Tools=== | |||
The prognosis in patients with heart failure can be assessed using a variety of risk stratification tools and cardiopulmonary exercise testing. Clinical prediction rules use a composite of clinical factors such as lab tests and blood pressure to estimate prognosis. Among several [[clinical prediction rule]]s for assessing the prognosis in acute heart failure, the 'EFFECT rule' slightly outperformed other rules in stratifying patients and identifying those at low risk of death during hospitalization or within 30 days.<ref name="pmid17449141">{{cite journal |author=Auble TE, Hsieh M, McCausland JB, Yealy DM |title=Comparison of four clinical prediction rules for estimating risk in heart failure |journal=Annals of emergency medicine |volume=50 |issue=2 |pages=127–35, 135.e1–2 |year=2007 |pmid=17449141 |doi=10.1016/j.annemergmed.2007.02.017}}</ref> Other simpler methods for identifying low risk patients include the: | |||
* ADHERE Tree rule which indicates that patients with [[blood urea nitrogen]] < 43 mg/dl and [[systolic blood pressure]] at least 115 mm Hg have less than 10% chance of inpatient death or complications. | |||
* BWH rule indicates that patients with [[systolic blood pressure]] over 90 mm Hg, [[respiratory rate]] of 30 or less breaths per minute, [[serum sodium]] over 135 mmol/L, no new [[ST-T wave changes]] have less than 10% chance of inpatient death or complications. | |||
A very important method for assessing prognosis in advanced heart failure patients is cardiopulmonary exercise testing (CPX testing). CPX testing is usually required prior to heart transplantation as an indicator of prognosis. Cardiopulmonary exercise testing involves measurement of exhaled oxygen and carbon dioxide during exercise. The peak oxygen consumption (VO2 max) is used as an indicator of prognosis. As a general rule, a VO2 max less than 12-14 cc/kg/min indicates a poor survival and suggests that the patient may be a candidate for a [[heart transplant]]. Patients with a VO2 max<10 cc/kg/min have clearly poorer prognosis. The most recent International Society for Heart and Lung Transplantation (ISHLT) guidelines<ref>{{cite web |url=http://www.jhltonline.org/article/PIIS1053249806004608/fulltext#sec1 |title=Evaluation of listing criteria for cardiac transplantation |author=Mandeep R. Mehra ''et al'' |work=Journal of Heart and Lung Transplantation |publisher= |accessdate=8 April 2010}}</ref> also suggest two other parameters that can be used for evaluation of prognosis in advanced heart failure, the heart failure survival score and the use of a criterion of VE/VCO2 slope > 35 from the CPX test. The heart failure survival score is a score calculated using a combination of clinical predictors and the VO2 max from the cardiopulmonary exercise test. | |||
===Mortality Associated with Heart Failure=== | ===Mortality Associated with Heart Failure=== | ||
Based on the 44-year follow-up of the NHLBI’s Framingham Heart Study: | Based on the 44-year follow-up of the NHLBI’s Framingham Heart Study: | ||
*80% of men and 70% of women under age 65 who have [[heart failure]] will die within following 8 years. | *80% of men and 70% of women under age 65 who have [[heart failure]] will die within following 8 years. | ||
| Line 34: | Line 77: | ||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
{{ | {{WikiDoc Help Menu}} | ||
{{ | {{WikiDoc Sources}} | ||
[[Category:Cardiology]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Intensive care medicine]] | |||
[[Category:Medicine]] | |||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Up-To-Date cardiology]] | [[Category:Up-To-Date cardiology]] | ||
Latest revision as of 10:37, 11 February 2022
 |
Resident Survival Guide |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Saleh El Dassouki, M.D. [3]; Atif Mohammad, M.D.
Overview
Heart failure is associated with significantly reduced physical and mental health, resulting in a markedly decreased quality of life. Congestive heart failure is also associated with a poor prognosis. If left untreated, heart failure may result in death due to complications associated with the condition. Heart failure resulting from atherosclerotic coronary artery disease has been shown to be associated with higher incidence of fatal events compared to heart failure that results from other cardiac diseases. Heart failure is a progressive disease with a major impact on the patient's quality of life. With the exception of heart failure caused by reversible conditions, the condition usually worsens with time. Although some people survive many years, progressive disease is associated with an overall annual mortality rate of 10%. In the Framingham experience, 80% of men and 70% of women with heart failure who were under 65 years of age had died within 8 years of the diagnosis.
Natural History
- If left untreated, heart failure may result in death due to complications associated with the condition. Heart failure is a progressive disease with a major impact on the patient's quality of life.
- Heart failure resulting from atherosclerotic coronary artery disease has been shown to be associated with higher incidence of fatal events compared to heart failure that results from other cardiac diseases
- Initiation of therapy for heart failure may lead to stabilization of the patient's clinical condition which is referred to as the stability phase.[1]
- Months to years following the stability phase, the patient functional status may decline resulting in multiple hospitalizations and eventually the condition may become refractory to treatment whn ventricular remodeling sets in.[2]
- Once refractory, heart failure may be managed titration of pharmacological therapy and by the use to left ventricular assist devices and cardiac transplantation.
- Common Triggers for referral to heart failure specialist are:[3]
- New-onset HF (regardless of EF): Refer for evaluation of etiology, therapies base on the guideline, evaluation by advanced imaging, endomyocardial biopsy, or genetic testing
- Chronic HF with high-risk features, such as development or persistence of one or more of the following risk factors:
- Need for chronic intravenous inotropes
- Persistent NYHA functional class III–IV symptoms of congestion or profound fatigue
- Systolic blood pressure ≤90 mm Hg or symptomatic hypotension
- Creatinine ≥1.8 mg/dL or BUN ≥43 mg/dL
- Initiation of atrial fibrillation, ventricular arrhythmias, or repetitive ICD shocks
- Two or more emergency department visits or hospitalizations for worsening HF in the prior 12 months
- Inability to tolerate optimally dosed beta-blockers and/or ACEI/ARB/ARNI and/or aldosterone antagonists
- Clinical deterioration, by worsening edema, increase biomarkers (BNP, NT-proBNP, others), worsened exercise testing, decompensated hemodynamics, or evidence of progressive remodeling on imaging
- High mortality risk using a validated risk model such as the Seattle Heart Failure Model
- Persistently reduced LVEF ≤ 35% despite GDMT for ≥3 months: refer for device therapy in those patients without prior placement of ICD or CRT, unless device therapy is contraindicated or inconsistent with overall goals of care
- Second opinion needed regarding etiology of HF, for example:
- Coronary ischemia and possibility of the need for revascularization
- Valvular heart disease and possibility of the need for valve repair
- Suspected myocarditis
- Suspected specific cardiomyopathies ( hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, Chagas disease, restrictive cardiomyopathy, cardiac sarcoidosis, amyloid, aortic stenosis)
- Annual review needed for patients with established advanced HF
- Assessment of patient for participation in a clinical trial
Complications
1. Cardiac Arrhythmias:
- Ventricular tachycardia and ventricular fibrillation can occur as serious complications of heart failure when its pump function is severely impaired. This further worsens the cardiac output and even possible death.
- Atrial fibrillation which is rapid beating of atrium without optimal forward pumping of blood is another complication of heart failure which occurs as a result of resistance to blood flow from atrium to ventricles. These patients are at increased risk of stroke.
- Left bundle branch block is an abnormality in electrical conduction in the heart.
2. Pulmonary Congestion:
- Pulmonary congestion which occur in left ventricular failure can cause pulmonary edema.
- Venous stasis and pedal edema can occur as a complication of right heart failure. These conditions predispose patients to venous ulcers, infections and cellulites.
- Cardiac cirrhosis occurs as a result of hepatic venous congestion. This can lead to coma and even death [4].
3. Angina and myocardial infarction: Cardiac ischemia and infarction can also occur when heart failure patients undergo exertion. With LV dilation, LV wall stress increases, and this increases the risk of angina. Autopsy studies demonstrate that plaque rupture and coronary thrombosis is a common mode of death in patients with congestive heart failure.
4. Renal failure: Renal impairment can occur secondary to decreased renal perfusion. This further worsens heart failure by fluid retention.
5. Cardiac cachexia: Unintentional rapid weight loss (a loss of at least 7.5% of normal weight within 6 months) can occur in chronic heart failure[5]. This is a bad prognostic factor.
Prognosis
Risk Stratification Tools
The prognosis in patients with heart failure can be assessed using a variety of risk stratification tools and cardiopulmonary exercise testing. Clinical prediction rules use a composite of clinical factors such as lab tests and blood pressure to estimate prognosis. Among several clinical prediction rules for assessing the prognosis in acute heart failure, the 'EFFECT rule' slightly outperformed other rules in stratifying patients and identifying those at low risk of death during hospitalization or within 30 days.[6] Other simpler methods for identifying low risk patients include the:
- ADHERE Tree rule which indicates that patients with blood urea nitrogen < 43 mg/dl and systolic blood pressure at least 115 mm Hg have less than 10% chance of inpatient death or complications.
- BWH rule indicates that patients with systolic blood pressure over 90 mm Hg, respiratory rate of 30 or less breaths per minute, serum sodium over 135 mmol/L, no new ST-T wave changes have less than 10% chance of inpatient death or complications.
A very important method for assessing prognosis in advanced heart failure patients is cardiopulmonary exercise testing (CPX testing). CPX testing is usually required prior to heart transplantation as an indicator of prognosis. Cardiopulmonary exercise testing involves measurement of exhaled oxygen and carbon dioxide during exercise. The peak oxygen consumption (VO2 max) is used as an indicator of prognosis. As a general rule, a VO2 max less than 12-14 cc/kg/min indicates a poor survival and suggests that the patient may be a candidate for a heart transplant. Patients with a VO2 max<10 cc/kg/min have clearly poorer prognosis. The most recent International Society for Heart and Lung Transplantation (ISHLT) guidelines[7] also suggest two other parameters that can be used for evaluation of prognosis in advanced heart failure, the heart failure survival score and the use of a criterion of VE/VCO2 slope > 35 from the CPX test. The heart failure survival score is a score calculated using a combination of clinical predictors and the VO2 max from the cardiopulmonary exercise test.
Mortality Associated with Heart Failure
Based on the 44-year follow-up of the NHLBI’s Framingham Heart Study:
- 80% of men and 70% of women under age 65 who have heart failure will die within following 8 years.
- In people diagnosed with heart failure, sudden cardiac death occurs at 6 to 9 times the rate of the general population.
- One in eight deaths has heart failure mentioned on the death certificate.
References
- ↑ Chaudhry SP, Stewart GC (July 2016). "Advanced Heart Failure: Prevalence, Natural History, and Prognosis". Heart Fail Clin. 12 (3): 323–33. doi:10.1016/j.hfc.2016.03.001. PMID 27371510.
- ↑ Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Riegel B, Spertus JA (April 2012). "Decision making in advanced heart failure: a scientific statement from the American Heart Association". Circulation. 125 (15): 1928–52. doi:10.1161/CIR.0b013e31824f2173. PMC 3893703. PMID 22392529.
- ↑ Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML, Kirklin JK, Weintraub WS (April 2021). "2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure)". Circ Cardiovasc Qual Outcomes. 14 (4): e000102. doi:10.1161/HCQ.0000000000000102. PMC 8059763 Check
|pmc=value (help). PMID 33755495 Check|pmid=value (help). - ↑ Moussavian SN, Dincsoy HP, Goodman S, Helm RA, Bozian RC (1982). "Severe hyperbilirubinemia and coma in chronic congestive heart failure". Digestive Diseases and Sciences. 27 (2): 175–80. PMID 7075414. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ Freeman LM (2009). "The pathophysiology of cardiac cachexia". Current Opinion in Supportive and Palliative Care. 3 (4): 276–81. doi:10.1097/SPC.0b013e32833237f1. PMID 19797959. Retrieved 2011-04-30. Unknown parameter
|month=ignored (help) - ↑ Auble TE, Hsieh M, McCausland JB, Yealy DM (2007). "Comparison of four clinical prediction rules for estimating risk in heart failure". Annals of emergency medicine. 50 (2): 127–35, 135.e1–2. doi:10.1016/j.annemergmed.2007.02.017. PMID 17449141.
- ↑ Mandeep R. Mehra; et al. "Evaluation of listing criteria for cardiac transplantation". Journal of Heart and Lung Transplantation. Retrieved 8 April 2010.